Evidence supporting the use of: Interferon gamma
For the health condition: Adenitis
Synopsis
Source of validity: Scientific
Rating (out of 5): 4
Interferon gamma is primarily used to treat chronic granulomatous disease (CGD), a rare inherited immunodeficiency that often presents with recurrent infections and granuloma formation, including adenitis (inflammation of lymph nodes). The scientific justification for its use is based on its immunomodulatory properties: Interferon gamma enhances the microbicidal activity of phagocytes, particularly by increasing the oxidative burst required to kill certain bacteria and fungi. Multiple clinical trials and case studies have demonstrated that regular administration of Interferon gamma significantly reduces the frequency and severity of serious infections, including lymphadenitis, in patients with CGD. Its use is FDA-approved for this indication. The evidence supporting Interferon gamma for adenitis unrelated to CGD or similar immunodeficiencies is limited or lacking; thus, its use is specifically validated in the context of particular underlying conditions rather than for adenitis as a general symptom. The rating reflects the robust evidence for its use in CGD-associated adenitis but not for other forms of lymph node inflammation. Key references include randomized controlled trials (such as The International Chronic Granulomatous Disease Cooperative Study, 1991) and systematic reviews. In summary, Interferon gamma is scientifically validated for use in supporting the immune system in patients with CGD who develop adenitis, with strong clinical evidence backing its efficacy in this setting.
